The medical cannabis product is launched under the brand IndiMed and manufactured at Aurora's EU-GMP facility in Leuna, Germany.

Imexpharm Corporation reported VND2,205 billion (US$87.3 million) in net revenue for 2024, marking a 10.6% year-on-year increase.

Aurora Cannabis (ACB) announces the launch of the company’s first German-cultivated medical cannabis product, under the brand IndiMed.

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces today the launch of the company's first German-cultivated medical cannabis product, ...